Innovative Cancer Treatment: Platinum-Based Drugs and Immunotherapy

Maria Babak shared a post by The Babak Lab on LinkedIn:

“This research sheds light on a cutting-edge approach in cancer treatment—platinum-based drugs inducing Immunogenic Cell Death (ICD).

The combination of chemotherapy and immunotherapy opens up new avenues for less toxic and more effective cancer treatments.

By exploring how these compounds work to stimulate the immune system, the research highlights an innovative strategy that could revolutionize how we fight cancer.

Check it out to learn how science is merging two powerful treatment methods to enhance outcomes for patients!”

Quoting The Babak Lab’s post:

“Innovative Cancer Treatment: Platinum-Based Drugs and Immunotherapy.

In recent years, researchers have explored Immunogenic Cell Death (ICD) as a powerful mechanism in fighting cancer.

Traditional platinum-based drugs like cisplatin, while effective, often come with high toxicity and drug resistance. But now, there’s hope on the horizon!

Key Highlights:

• Oxaliplatin’s New Path

A platinum-based drug that induces ICD by causing ribosomal stress, showing promise in treating colorectal cancer.

• Novel Platinum Derivatives

These compounds stimulate the immune system, allowing the body to better target and destroy cancer cells.

• Chemo and Immunotherapy Synergy

By combining traditional chemotherapy with immune-activating properties, we can lower drug doses and minimize side effects while boosting cancer-killing power.

The future of cancer treatment may lie in chemoimmunotherapy, and platinum-based ICD inducers could lead the charge!

Read the original article for more details.”

Source: Maria Babak/LinkedIn and The Babak Lab/LinkedIn

Dr. Maria Babak is the Head of The Babak Lab and an Assistant Professor at the City University of Hong Kong. In November 2020, she joined the City University of Hong Kong as an assistant professor. Dr. Babak received the Graeme Hanson-AsBIC Early Career Award in 2022.
Her research interests are at the intersection of chemistry, biology, and medicine, with a focus on the discovery and preclinical development of anticancer drugs for resistant and aggressive cancers with limited treatment options, such as malignant pleural mesothelioma and brain metastases.